Evaluation of factors associated with platinum-sensitivity status and survival in limited-stage small cell lung cancer patients treated with chemoradiotherapy

Abstract

In this retrospective study, we analyzed the association of clinicopathological factors and therapeutic plans with platinum-sensitivity status and survival of limited-stage small cell lung cancer (LS-SCLC) patients. We enrolled 452 LS-SCLC patients with 279 platinum sensitive and 173 platinum refractory patients. The low serum neuro-specific enolase levels (NSE; <i>p</i> = 0.011), neutrophil-to-lymphocyte ratios (NLR; <i>p</i> = 0.013) and higher objective response rates (<i>p</i> = 0.003) were associated with sensitive group but not the refractory group. Multivariate analysis showed that treatment modality (HR = 0.267, <i>p</i> < 0.001), serum lactate dehydrogenase (LDH; HR = 1.894, <i>p</i> = 0.016), NLR (HR = 2.043, <i>p</i> = 0.043) and platinum-sensitivity status (HR = 0.561, <i>p</i> = 0.036) were independent prognostic factors for survival. We further showed that the numbers of chemotherapy cycles and response to first-line therapy were independent prognostic factors for refractory patients only. Our study demonstrates that platinum-sensitivity status is of prognostic importance, as it is strongly associated with survival in LS-SCLC patients.